Grail partners with Samsung C&T to commercialize Galleri cancer test in South Korea

Grail

Grail

GRAL

0.00
  • Grail entered a planned commercial collaboration with Samsung C&T to launch the Galleri multi-cancer early detection test in South Korea.
  • Partnership includes potential expansion into Japan or Singapore, subject to regulatory approvals and other conditions.
  • Samsung affiliates funded the rollout with a $110 million equity investment at $70.05 per share, supporting international expansion.
  • Initial Galleri testing for the South Korea program will be run from Grail’s clinical laboratory in Research Triangle Park, North Carolina.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.